8-K - SHPH - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2024

SHUTTLE

PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41488	82-5089826
(State<br> or other jurisdiction<br><br> <br>of<br> incorporation)	(Commission<br><br> <br>File<br> Number)	(IRS<br> Employer<br><br> <br>Identification<br> No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title<br> of each class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered
Common<br> Stock $0.00001 per share	SHPH	The<br> Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item1.01 Entry into a Material Definitive Agreement.

On August 8, 2024, Shuttle Pharmaceuticals, Inc. (“Shuttle Pharma”), a wholly owned subsidiary of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), entered into a work order (the “Work Order”) with Theradex Systems, Inc., a New Jersey contract research organization (“CRO”) for purposes of supporting Shuttle Pharma’s “Phase 2 Study of Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated MGMT Promotor.” The Phase 2 clinical trial was previously approved by the U.S. Food and Drug Administration, or the FDA, in January 2024 and the Institutional Review Board on June 21, 2024. As such, Shuttle Pharma is now in the process of signing up six clinical sites where the clinical studies will be performed – two of which have completed initial site initiation visits and one of which is ready to enroll patients – and where the CRO will oversee such studies.

Under the terms of the Work Order, the CRO will oversee the studies for a period of 53 months (the “Term”), including overseeing and monitoring the regulatory aspects of the Phase 2 clinical trial, and managing the documentation surrounding the clinical trial in exchange for a fee of approximately $2.3 million, payable in stages and based upon services performed during the Term of the study. The underlying terms of the Work Order are governed by a master service agreement, dated November 1, 2018 (the “MSA”), between Shuttle Pharma and the CRO, which contains standard intellectual property, confidentiality, indemnification and insurance provisions, ensuring that Shuttle Pharma will own all intellectual property developed from the Phase 2 clinical trial.

The foregoing description of the Work Order and the MSA do not purport to be complete and are qualified in their entirety by reference to the full text of such agreement, which are filed herewith as Exhibits 10.1 and 10.2 and are incorporated by reference herein.

Item8.01 Other Events.

On August 14, 2024, the Company issued a press release announcing that it had entered into agreements with two of the six planned locations that will administer the Company’s Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. A copy of the press release is furnished herewith.

The information in this Item 8.01 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 8.01.

Forward-LookingStatements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may relate to statements concerning future results, strategy and plans of the Company (including certain statements which may be identified by the use of the words “plans,” “expects,” “does not expect,” “estimated,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates,” “does not anticipate” or “believes,” or variations of such words and phrases, or state that certain actions, events or results “may,” “could,” “would,” “might,” “projects,” “will,” “will be taken,” “occur” or “be achieved”). Forward-looking statements are based on the opinions and estimates of management of the Company, as of the date such statements are made, and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Additional information on these and other factors that may cause actual results and the Company’s performance to differ materially is included in the Company’s periodic reports filed with the Securities and Exchange Commission, or the SEC. Copies of the Company’s filings with the SEC are available publicly on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligations to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
10.1	Work Order, dated August 8, 2024, between Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc.*
10.2	Master Services Agreement, dated November 1, 2018, between Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc.
99.1	Press Release dated August 14, 2024.
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)

*certain portions of this exhibit have been redacted because it (i) is not material and (ii) is the type of information that the company normally treats as private or confidential.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SHUTTLE<br> PHARMACEUTICALS HOLDINGS, INC.
Dated:<br> August 14, 2024
	By:	/s/ Anatoly Dritschilo
	Name:	Anatoly<br> Dritschilo
	Title:	Chief<br> Executive Officer

Exhibit10.1

Portionsof this agreement have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Redactions are indicated with “[***].”

WorkOrder #3

Theradex Systems, Inc. (hereinafter “Theradex Oncology”)

to assist

Shuttle Pharmaceuticals, Inc. (hereinafter “Shuttle”)

with the Scope of Work associated with:

Phase2 Study of IPdR as a Radiation Sensitizing Agent During Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype Glioblastoma withUnmethylated MGMT Promoter

30 July 2024

Prepared For:	Michael<br> Vander Hoek<br><br> <br>VP,<br> Regulatory<br><br> <br>Shuttle<br> Pharmaceuticals, Inc.<br><br> <br>401<br> Professional Drive<br><br> <br>Suite<br> 260<br><br> <br>Gaithersburg,<br> MD 20879 USA<br><br> <br>Email:<br> M.Vanderhoek@shuttlepharma.org
Prepared By:	[*]<br><br> <br>[]<br><br> <br>The<br> Pinnacle, Station Way<br><br> <br>Crawley<br><br> <br>West<br> Sussex UK<br><br> <br>RH10<br> 1JH<br><br> <br>Phone:<br> []<br><br> <br>Email:<br> [**]

| Page 1 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

WorkOrder #3 to the Master Service Agreement dated 01 November 2018 between Shuttle and Theradex Oncology (hereinafter “MSA”),

to assist Shuttle. with the Scope of Work associated with

“Phase2 Study of IPdR as a Radiation Sensitizing Agent During Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype Glioblastoma withUnmethylated MGMT Promoter”

(hereinafter “Project”)

This Work Order details the services that Theradex Oncology shall provide to Shuttle pertaining to the aforementioned Project. Upon signature by authorized representatives of Theradex Oncology and Shuttle, this Work Order shall be incorporated by reference and made a part of the MSA between Shuttle and Theradex Oncology.

This Work Order is effective as of 01 March 2024 and is estimated to be completed by 31 July 2028 (hereinafter “Term”). The Term of this Work Order may be extended upon the written request of Shuttle and the mutual agreement by Shuttle and Theradex Oncology.

Of note: the budget, dated 23 July 2024, accompanying this WO is limited in $ amount and time. It will only cover the first year from February 2024 till January 2025 and is limited to US$2,237,544. A Change Order covering subsequent year(s) and increased $ amount will need to be in place from January 2025 onwards.

The services under this Work Order shall be conducted under and subject to the terms and conditions of the MSA.

| Page 2 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

ACKNOWLEDGED, ACCEPTED AND AGREED TO:

Theradex Oncology:
/s/<br> Margaret Valnoski	08-August-2024
Margaret<br> Valnoski	Date
President<br> / CEO
Theradex<br> Systems, Inc.
Shuttle
	August<br> 8, 2024
Michael<br> P Vander Hoek	Date
VP,<br> Regulatory
Shuttle<br> Pharmaceuticals, Inc.

| Page 3 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

General Terms

A.	Shuttle<br> acknowledges that this Work Order does not include any applicable VAT or other tax to which Shuttle may be subject. Such taxes will<br> be the sole responsibility of Shuttle.
B.	Theradex<br> will utilize a milestone billing payment schedule for this Project. However, Theradex will submit to Shuttle a monthly invoice detailing<br> pass-through expenses that are rendered to Shuttle.
C.	Payment<br> will be made by Shuttle in accordance with the terms stipulated in the Master Service Agreement dated 01 November 2018.
D.	Shuttle<br> agrees not to employ or seek to employ any Theradex employee for a period of six (6) months following the termination of all contracts<br> of Shuttle with Theradex, or a period of six (6) months following the departure of the employee from Theradex, whichever is later.
E.	Theradex<br> will initiate quarterly contract review meetings with Shuttle to monitor the progress of billings and milestone activities. The meetings’<br> purpose is to 1) determine the level of progress by major service activity by Theradex and 2) ensure activities have remained in<br> scope to the Work Order and the budget has not, or is not anticipated to exceed, the Work Order.
F.	Theradex<br> services will be conducted in compliance with Theradex Standard Operating Procedures (SOPs), unless otherwise specified. Should [Shuttle]<br> require that Theradex conduct certain services in compliance with Shuttle’s SOPs, adjustment of the Study Budget may be necessary.

| Page 4 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

TheradexOncology Project Team

The Project Team members and their roles are outlined in the Project Management Plan. Appendix 1: Theradex Oncology Scope of Work

1.1	Project<br> Assumptions
Lead-in<br> Period	5<br> months
---	---
Enrollment<br> Period	24<br> months
Average<br> Duration of Patient Treatment	2<br> months
Data<br> Lock	2<br> months
Clinical<br> Study Report	2<br> months
Long-Term<br> Follow Up	18<br> months
Total<br> Study Duration	53<br> months
Number<br> of Countries	1<br> (US)
Number<br> of Sites	6<br> sites
Number<br> of Patients Screened	65<br> (20% screen failure rate)
Number<br> of Patients Enrolled	54

Theradex Oncology services will be conducted in compliance with Theradex Oncology Standard Operating Procedures (SOPs), unless otherwise specified. Should Shuttle require Theradex Oncology conduct certain services in compliance with Shuttle’s SOPs, adjustment of the Study Budget may be necessary.

1.2	Project<br> Timeline
	Timeline
---	---	---
Task	Estimated<br><br> <br>Start Date	Estimated<br><br> <br>Completion Date
Start-up:<br> Final Protocol to First Patient In (FPI)	01<br> March 2024	31<br> July 2024
Recruitment:<br> FPI to Last Patient In (LPI)	01<br> August 2024	01<br> August 2026
Treatment:<br> LPI to Last Patient Out (LPO)	02<br> August 2026	01<br> October 2026
Database<br> Lock: LPO to Database Lock	02<br> October 2026	30<br> November 2026
Final<br> Report: Draft Report to Final Report	01<br> December 2026	31<br> January 2027
Long-Term<br> Follow Up	01<br> February 2027	31<br> July 2028
Total<br> Timeline	53<br> months

| Page 5 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | 1.3 | Study Set-up and Initiation | | --- | --- | | 1.3.1 | Feasibility | | --- | --- | | Task List | Shuttle | Theradex | | --- | --- | --- | | Conduct Feasibility to identify potential sites | X | | | Recruit back up sites | X | | | Replace sites that withdraw | X | | | Collection of CDAs | X | X | | Teleconferences with Sites | X | | | Questionnaire Development | X | | | Questionnaire Analysis | X | | | Prepare Feasibility Report | X | |

TheradexOncology will:

A.	Obtain<br> Confidential Disclosure Agreements (CDAs) from potential sites – if applicable.
Feasibility Assumptions
---	---
Total<br> number of sites to be assessed	6
1.3.2	Study Documents
---	---
Task List	Shuttle	Theradex
---	---	---
Protocol<br> Development, Review, and Approval	X
Model<br> ICF Template and Amendments Development	X
Develop<br> and Approve Country Specific ICF Templates and Amendments	X
Resolve<br> Country Specific Site Informed Consent Issues	X
Prepare<br> Study Operations Manual		X
Prepare<br> Regulatory Binder		X
Copy/Distribute<br> Protocol and IB		X

| Page 6 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

TheradexOncology will:

A.	Prepare<br> the Investigator Site File. The Investigator Site File describes study logistics and other issues related to the conduct of the study.<br> The Investigator Site File will be finalized prior to the first SIV. Theradex Oncology assumes two sponsor reviews of the Investigator<br> Site File.
B.	Prepare<br> the Pharmacy Binder. The Pharmacy Binder describes study logistics and other issues related to the conduct of the study. The Pharmacy<br> Binder will be finalized prior to the first SIV. Theradex Oncology assumes two sponsor reviews of the Pharmacy Binder.
C.	Distribute<br> protocol, investigator brochure, study manuals, and project documentation to study site.
D.	Prepare<br> and submit Annual Safety Reports/Development safety reports to regulatory authorities.
1.3.3	Regulatory Documents
---	---
Task List	Shuttle	Theradex
---	---	---
Obtain<br> initial IRB/IEC documents		X
Collect<br> financial disclosure for each investigator		X
IRB<br> submission of documents		X

TheradexOncology will:

A.	Collect<br> initial site IRB/IEC regulatory documents and financial disclosures. Theradex Oncology will maintain copies of this documentation<br> and provide full sets to Shuttle at the end of the study or at any time as requested by Shuttle. The regulatory documents will be<br> available for Shuttle’s review on the Theradex Oncology Client Portal. The regulatory documentation to be collected will include:
○	IRB<br> approval of protocol and informed consent document
---	---
○	Evidence<br> of Investigator Brochure (IB) submission to IRB
○	IRB<br> membership list
○	Financial<br> Disclosure (FD) form
○	Any<br> other documents specified by individual national agencies/authorities
○	Theradex<br> Oncology will provide Shuttle additional documentation upon request
B.	Submit<br> IRB documents to study sites local/central IRB and track timelines and progress through IRB<br> approval.
---	---

| Page 7 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

1.3.4	Clinical<br> Sites
Task List	Shuttle	Theradex
---	---	---
Prepare<br> site contract & budget template		X
Negotiate<br> budget and execute CTAs		X
Administer<br> grant payments		X

TheradexOncology will:

A.	Prepare<br> site contract and budget templates in collaboration with Shuttle. Finalize contract and budget upon Shuttle’s approval.
B.	Negotiate<br> study budgets and clinical study agreements with the study site(s). Theradex Oncology will include the fully executed final agreements<br> in the Electronic Trial Master File (eTMF) for site activation.
C.	Administer<br> payment of investigator grants. Theradex Oncology will manage and administer grant payments for all sites.
1.3.5	Qualification Visits
---	---
Task List	Shuttle	Theradex
---	---	---
Prepare<br> agenda and presentation materials/slides	X
Prepare<br> visit confirmation letters	X
Conduct<br> site qualification visits	X
Submit<br> Follow up letter	X
Provide<br> site qualification report	X

TheradexOncology will:

Conduct one pre-study (site qualification) visit to the study site(s). Theradex Oncology will determine the qualification of the sites for study conduct and subject recruitment, as well as the experience and availability of the Investigator for the supervision and conduct of the trial. The topics that will be evaluated during the qualification will be outlined in the Monitoring Plan.

| Page 8 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | Qualification Visit (QV) Assumptions | | | | | --- | --- | --- | --- | | | On-Site | Remote | QV Call | | Number of Visits | N/A | N/A | 6 Visits | | Visit Prep Time | N/A | N/A | 6.5 hours | | Visit On-Site Time | N/A | N/A | | | Visit Report /Report review Time | N/A | N/A | | | Visit Findings Follow up Time | N/A | N/A | | | Visit Travel Time | N/A | N/A | N/A |

1.3.6	Initiation Visits
Task List	Shuttle	Theradex
---	---	---
Prepare<br> agenda and presentation materials/slides		X
Prepare<br> visit confirmation letters		X
Conduct<br> site initiation visits		X
Submit<br> follow-up letter		X
Provide<br> site initiation report		X

TheradexOncology will:

Conduct one study initiation visit (SIV) to study sites. (Note: Shuttle may elect to participate in the SIV as this is an opportunity to meet directly with the research staff. The Theradex Oncology Medical Monitor will participate to the SIV (about 1 hours is foreseen). The topics that will be presented and reviewed during the Site Initiation Visit will be outlined in the Monitoring Plan.

Site Initiation Visit (SIV) Assumptions
	On-Site	Remote
Number<br> of Visits	N/A	6<br> visits
Visit<br> Prep Time	N/A	2<br> hours
Visit<br> On-Site Time	N/A	8<br> hours
Visit<br> Report /Report review Time	N/A	4.5<br> hours
Visit<br> Findings Follow up Time	N/A	1.5<br> hours
Visit<br> Travel Time	N/A	N/A

| Page 9 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

1.4	Project Management
Task List	Shuttle	Theradex
---	---	---
Project<br> Management		X
Prepare<br> Project Management Plan		X
Approve<br> Project Management Plan	X
Prepare<br> Communication Plan		X
Approve<br> Communication Plan	X
Prepare<br> eTMF Plan		X
Approve<br> eTMF Plan	X
Prepare<br> Monitoring Plan		X
Approve<br> Monitoring Plan	X
Prepare<br> Risk Assessment Plan		X
Approve<br> Risk Assessment Plan	X
Prepare<br> Medical Plan		X
Approve<br> Medical Plan	X
Prepare<br> Safety Plan		X
Approve<br> Safety Plan	X
Lab/PK<br> Manual		X
Set<br> up electronic Trial Master File (Veeva Vault), including site files		X
Maintain<br> electronic Trial Master File		X
Project<br> Kick off Meeting	X	X
Project<br> Team Meetings (Theradex Oncology and Shuttle)	X	X
Internal<br> Team Meetings		X
Status<br> Reports via CTMS		X
Investigator<br> Site Safety Calls	X	X
Protocol<br> Deviation Meetings	X	X
Risk<br> Review Meetings	X	X
Quarterly<br> Budget Review Meetings	X	X
Steering<br> Committee Meetings	X	X

| Page 10 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

TheradexOncology will:

A.	Be<br> responsible for the day-to-day Project Management of this study in close collaboration with the Project Management personnel at Shuttle.<br> Theradex Oncology will provide Shuttle a primary contact (Project Manager) to coordinate all aspects of this study. Project management<br> responsibilities include, but are not limited to:
○	Maintaining<br> regular contact with Shuttle and functioning as the primary contact between the two companies.
---	---
○	Providing<br> day-to-day direction to the Theradex Oncology Project Team and resolving project issues among<br> team members, functional line managers, and other personnel when necessary.
○	Coordinating<br> communications within the entire Project Team. All contact with Shuttle will be documented<br> and filed in the project electronic Trial Master File.
○	Updating<br> Shuttle on an ongoing basis and offering solutions to any project-related issues, via regular<br> teleconferences.
○	Report<br> to Shuttle immediately when delays of milestones and deliverables occur or are foreseen,<br> including a proposed action plan to resolve issues and to ensure compliance with milestones<br> and deliverables.
B.	Prepare<br> the Project Management Plan. Theradex Oncology will prepare the Project Management Plan according to Theradex Oncology SOPs. Shuttle<br> will review and approve the Plan. Completion of the Project Management Plan is expected prior to the first Site Initiation Visit.<br> Theradex Oncology assumes two reviews from Suttle of the document.
---	---
C.	Prepare<br> the study Communication Plan. Theradex Oncology will prepare the Communication Plan according to Theradex Oncology SOPs. Shuttle<br> will review and approve the Plan. Completion of the Communication Plan is expected during the first month of the contract. Theradex<br> Oncology assumes two reviews from Shuttle of the document.
D.	Prepare<br> the eTMF Plan. Theradex Oncology will prepare the eTMF Plan according to Theradex Oncology SOP. Theradex Oncology assumes two Shuttle<br> reviews of the document.
E.	Prepare<br> the study Monitoring Plan. Theradex Oncology will prepare the plan according to Theradex Oncology SOPs. Shuttle will review and approve<br> the Plan. Theradex Oncology assumes two Shuttle reviews of the document. Completion of the Monitoring Plan is expected prior to the<br> first routine monitoring visit.
F.	Prepare<br> the study Risk Assessment Plan. Theradex Oncology will prepare the Risk Assessment Plan according to Theradex Oncology SOPs. Shuttle<br> will review and approve the Plan. Completion of the Risk Assessment Plan is expected prior to the first site activated. Theradex<br> Oncology assumes two Shuttle reviews of the document.

| Page 11 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | G. | Prepare the Medical Plan. Theradex Oncology will prepare the Medical Plan according to Theradex Oncology’s SOPs. Shuttle will review and approve the Plan. Completion of the Medical Plan is expected to be finalized prior to the first Site Initiation Visit. Theradex Oncology assumes two Shuttle reviews of the document. | | --- | --- | | H. | Prepare the study Safety Management Plan. Theradex Oncology will prepare the Safety Management Plan according to Theradex Oncology SOPs. Shuttle will review and approve the plan. The Safety Management Plan will be finalized prior to the first SIV. Theradex Oncology assumes two Shuttle reviews of the document. | | I. | Prepare Lab/PK manual. The Lab/PK manual describes the sample collection, handling and logistics for the study. The Lab/PK manual should be finalized prior to the first site initiation visit. Theradex Oncology assumes two reviews of the Lab/PK manual. | | J. | Create and maintain the eTMF in Veeva Vault for Shuttle. Veeva Vault is a tool which provides access to documents posted by Theradex Oncology such as PDFs of the monitoring visit reports, telephone communication logs, meeting minutes, and IRB records, documents from 3rd Party Vendors, etc. The Theradex Oncology project staff will utilize Veeva Vault to rapidly disseminate project specific information to all study team members. Shuttle will have access to the eTMF. Theradex Oncology has assumed that a total of 3,032 final archived documents will be uploaded to the eTMF. In case the number of documents goes beyond 3,032; Shuttle and Theradex Oncology will need to revise the cost for the eTMF. Theradex to continually monitor document uploads, track against anticipated archive number, and provide to Shuttle advanced projections of the anticipated number to give advanced warning of exceeding these projections. Details will be provided in the eTMF Plan. TMF provision/archival is anticipated to occur within two months of completion of the final CSR. |

| Page 12 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | K. | Conduct a kick-off meeting with representatives of Shuttle at the beginning of the project. | | --- | --- |

The purpose of this meeting will be to discuss the following:

○	Primary<br> points of contact within each company
○	Review<br> the roles and responsibilities of team members
○	Review<br> the study procedures, protocol, and important study endpoints
○	Reiterate<br> reporting requirements
○	Review<br> the Communication Plan
○	Review<br> the project timelines and scope of work
○	Review<br> the Risk Management Plan and escalation plans
○	Clarify<br> any other ad hoc issues

The Theradex Oncology Project Manager will lead the presentations to the group regarding Theradex Oncology’s responsibilities. The project team members attending the meeting will be the Project Manager, Project Coordinator, CRA(s), Medical Monitor, Safety Coordinator, Data Analyst, and Document Specialist personnel as appropriate for the project.

Kick Off Meeting Assumptions
Estimated<br> Meeting attendees	9
Meeting<br> frequency	Once
Meeting<br> duration	4<br> hours
L.	Theradex<br> Oncology and representatives of Shuttle (including external vendors) will meet, via teleconference,<br> for trial logistic and operations meetings during the study. Theradex Oncology participants<br> will include the Project Manager for each meeting. Other study team members such as Data<br> Management and CRA(s) will join regularly as appropriate for the project. It is anticipated<br> that the Medical Monitor will join half the scheduled calls. Topics to be discussed during<br> the teleconferences include, but are not limited to; status of site activation, patient recruitment<br> and enrollment, monitoring visits and data completion status, drug distribution, and site<br> management problems and solutions.
---	---
Project Teleconference Assumptions
---	---
Teleconference<br> attendees (on average)	2-3
Teleconference<br> frequency	Monthly
Meeting<br> duration	1<br> hour

| Page 13 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | M. | Theradex Oncology will conduct regular internal project team meetings. These meetings should include representatives from each functional group, as needed, depending on the issues and the stage of the project. | | --- | --- | | Internal Meeting and Discussion Assumptions | | | --- | --- | | Team members | 8 | | Meeting communication frequency | Monthly | | Time allotted | 1 hour | | N. | Update the trial status on the Theradex Oncology CTMS. Shuttle will have 24/7 access to the CTMS. For budgeting purposes, it is assumed that Theradex Oncology’s standard information from the CTMS will be provided. | | --- | --- | | O. | Theradex Oncology will conduct Investigator Site Safety Call with Shuttle and the representatives from the study sites (Principal Investigator, Sub-Investigator, etc.). Theradex Oncology participants will include the Medical Monitor and the Clinical Operations team. Topics to be discussed will include, but not be limited to the patient safety, patient recruitment and potential patient(s). | | --- | --- | | Investigator Site Safety Calls | | | --- | --- | | Team members | 2-3 | | Meeting communication frequency | Every 2 weeks | | Time allotted | 0.5 hours | | P. | Theradex Oncology will conduct Protocol Deviation Meetings with Shuttle. Theradex Oncology participants will include the Clinical Operations team. Topics to be discussed will include, but not be limited to the protocol deviations and their impact on the overall study conduct. | | --- | --- | | Protocol Deviation Meeting | | | --- | --- | | Team members | 2-3 | | Meeting communication frequency | Quarterly | | Time allotted | 1 hour |

| Page 14 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | Q. | Theradex Oncology will conduct periodic Risk Review Meetings with Shuttle. Theradex Oncology participants will include the Clinical Operations team. Topics to be discussed will include, but not be limited to the study risks, mitigations and actions. | | --- | --- | | Risk Review Meeting | | | --- | --- | | Team members | 3-4 | | Meeting communication frequency | Quarterly | | Time allotted | 1 hour | | R. | Theradex Oncology will conduct Quarterly Budget Review Meetings with Shuttle. Theradex Oncology participants may/will include the Executive Management team (optional), the Project Manager, and the Business Operations team. Topics to be discussed will include, but not be limited to: the study budget (actuals vs contracted costs), Investigator fees and budget forecast. | | --- | --- | | Quarterly Budget Review Meeting | | | --- | --- | | Team members | 2-3 | | Meeting communication frequency | Quarterly | | Time allotted | 0.5 hours | | S. | Theradex Oncology will conduct periodic Steering Committee meetings. Theradex Oncology participants will include the Executive Management team, the Project Manager, and the Business Operations team. Topics to be discussed will include, but not be limited to: study timeline, patient accrual, site performance, patient data status, and study budget. | | --- | --- | | Steering Committee Meeting | | | --- | --- | | Team members | 3 | | Meeting communication frequency | Yearly | | Time allotted | 0.5 hours |

| Page 15 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | Internal Steering Committee Meeting | | | --- | --- | | Team members | 4 | | Meeting communication frequency | Every 6 months | | Time allotted | 0.25 hours | | 1.5 | Monitoring Services | | --- | --- | | 1.5.1 | Interim Monitoring / Close-out Visits | | --- | --- | | Task List | Shuttle | Theradex | | --- | --- | --- | | On-Site Monitoring | | | | Prepare Visit Confirmation letters | | X | | Conduct monitoring visits | | X | | Verify 100% of source documentation | | X | | Review drug records/drug accountability | | X | | Review site study file | | X | | Provide site monitoring reports to Shuttle | | X | | Submit Follow up letter to site | | X | | Interim CRF Review | | X | | Close-Out Visits | | | | Prepare Visit Confirmation letters | | X | | Conduct site close-out visits | | X | | Submit Follow up letter | | X | | Provide close-out trip report | | X | | Perform post-study drug accountability | | X | | Study drug return/destruction | | X |

TheradexOncology will:

Conduct Routine Monitoring Visits (RMVs) following enrollment of the first patient. Monitoring visits will be conducted in compliance with the monitoring plan that is prepared prior to the first monitoring visit. In general, monitoring visits will be conducted approximately every six weeks depending on enrollment, with more frequent visits occurring during the initial part of the study. The activities that Theradex Oncology will complete during the RMVs will be outlined in the Monitoring Plan.

| Page 16 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | B. | Assumptions for the number of Routine Monitoring Days: it is estimated that 234 eCRFs will be monitored per patient remaining on treatment for 2 months and long-term follow up. Some ‘ad-hoc’ monitoring visits have also been foreseen in case additional visits need to be performed in preparation of the futility analysis or other unforeseen deadlines. On average, a CRA is expected to monitor/source data verify 80 eCRFs per monitoring day. Therefore, on average, it is expected that 3.2 monitoring days will be required to complete monitoring of a patient. In total, for 40 patients remaining on treatment for 2 months and long-term follow up, it is estimated that 127 monitoring days, divided over 1- and 2-day on-site and remote RMVs as specified in the below table will be required. In case patients, on average, stay on study longer than 2 months, or interim data cuts are to be performed the assumptions will need to be revised. | | --- | --- | | Routine Monitoring Visit (RMV) Assumptions | | | | --- | --- | --- | | 1 Day RMVs | On-Site | Remote | | Number of Visits | 9 Visits | 67 Visits | | Visit Prep Time | 3 hours | 3 hours | | Visit On-Site Time | 8 hours | 8 hours | | Visit Report /Report review Time | 4.5 hours | 4.5 hours | | Visit Findings Follow up Time | 2 hours | 2 hours | | Visit Travel Time | 6 hours | N/A | | 2 Day RMVs | On-Site | Remote | | Number of Visits | 5 Visits | 48 Visits | | Visit Prep Time | 3.5 hours | 3.5 hours | | Visit On-Site Time | 16 hours | 16 hours | | Visit Report /Report review Time | 5.5 hours | 5.5 hours | | Visit Findings Follow up Time | 2.5 hours | 2.5 hours | | Visit Travel Time | 6 hours | N/A | | C. | Conduct Long-term follow up remote monitoring calls. 2 calls per site have been foreseen. | | --- | --- | | D. | Conduct one study close out visit to each study site. Where possible, the final monitoring visit to the site will be a close out visit. The close out visit will be conducted at the site that received study medication and/or enrolled patient(s). Visits will be scheduled as soon as possible after the last patient has completed the study. The activities that Theradex Oncology will complete during the close out visits will be outlined in the Monitoring Plan. |

| Page 17 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | Close Out Visit (COV) Assumptions | | | | --- | --- | --- | | | On-Site | Remote | | Number of Visits | 1 visit | 5 Visits | | Visit Prep Time | 3 hours | 3 hours | | Visit On-Site Time | 4 hours | 4 hours | | Visit Report /Report review Time | 5 hours | 4 hours | | Visit Findings Follow up Time | 2 hours | 1 hours | | Visit Travel Time | 6 hours | N/A |

E.	Co-Monitoring

Theradex Oncology acknowledges that Shuttle has the right to co-monitor the investigational sites with Theradex Oncology monitoring personnel. Theradex Oncology encourages Shuttle to take advantage of the co-monitoring right at the convenience of Shuttle.

1.5.2	Site Communication / Management
Task List	Shuttle	Theradex
---	---	---
Site<br> Questions/Management		X
Investigator<br> Safety and Site Teleconferences		X

TheradexOncology will:

Oversee management of the study sites. Site management includes, but is not limited to: all activities associated with managing the investigational site during study start-up, patient accrual, data cleaning and site close-out. Theradex Oncology will maintain regular contact with the sites to provide protocol/eCRF support, to train personnel on study tools, to schedule monitoring visits, and to address study conduct issues noted during monitoring visits. In addition, Theradex Oncology will respond to protocol and study administration queries and clinical questions from the study site. Theradex Oncology will not grant eligibility or protocol deviation waivers without the prior approval of Shuttle. Theradex Oncology will not permit adjustments to the study evaluation requirements or dose attenuation requirements without the approval of Shuttle.

| Page 18 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | 1.5.3 | Medical Monitoring and Pharmacovigilance | | --- | --- | | Task List | Shuttle | Theradex | | --- | --- | --- | | Medical Monitor | | X | | Safety Desk coverage after hours | | X | | Document and manage all SAEs | | X | | Develop and maintain safety database | | X | | Submit SAE reports to Sponsor and affiliates | | X | | Submit SAE reports to Regulatory Authorities | | X | | Prepare safety updates/Investigator Letter | | X | | Submit SAE to clinical sites | | X | | SAE reconciliation | | X |

TheradexOncology will:

A.	Provide<br> global medical monitoring coverage to answer all medical questions from the investigational<br> centers regarding patient eligibility, patient treatment, and protocol requirements. The<br> Medical Monitor will also assess and provide recommendations to Shuttle regarding eligibility<br> or protocol deviation waiver requests.
B.	Provide<br> Theradex Oncology Safety Desk coverage 24 hours a day, seven days a week to maintain safety<br> pharmacovigilance. Theradex Oncology Safety Desk will receive global SAE reports from the<br> study sites. A Theradex Oncology physician will assess every SAE report to determine whether<br> the SAE requires expedited reporting and then the SAE report and medical assessment will<br> be submitted to Shuttle. Theradex Oncology will forward SAE safety reports to the FDA and<br> clinical centers when criteria have been met for such action.
---	---
C.	Safety<br> data, which includes SAEs and data listings from the clinical database, will be reviewed<br> at a minimum of six-month intervals by the Theradex Oncology Medical Monitor or as warranted<br> based on the safety profile of the investigational product. The conclusions resulting from<br> the interim medical review and any emergent signals of drug-related toxicity will be communicated<br> to Shuttle per the Theradex Oncology Drug Safety Plan.
---	---
D.	Maintain<br> an E2B compliant SAE database and reconcile the SAE report data with the adverse event information<br> provided in the study database periodically during the course of the project. Defined variables<br> must match or have a logical correlation. Defined variables will be agreed upon prior to<br> the start of the study. Reconciliation of the SAE data with the adverse event data reported<br> in the study database will occur approximately every quarter following initiation of patient<br> enrollment. The last SAE reconciliation effort will occur just prior to database lock.
---	---

| Page 19 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | SAE and SUSAR Assumptions | | | --- | --- | | Total SAEs | 27 SAEs (50%) | | Total SUSARs | 3 (10% of SAEs) | | 1.6 | Statistical Analysis and Medical Writing Services | | --- | --- | | Task List | Shuttle | Theradex | | --- | --- | --- | | Prepare Randomization Plan | | X | | Approve Randomization Plan | X | | | Prepare Statistical Analysis Plan | | X | | Approve Statistical Analysis Plan | X | | | Prepare TLF Plan | | X | | Approve TLF Plan | X | | | Sample Size Calculations | | X | | Final Data Analysis | | X | | Prepare Clinical Study Report (CSR) template | X | | | Prepare CSR | X | | | CSR subsequent drafts – up to 2 drafts | X | | | Patient Narratives | X | | | Final CSR | X | |

TheradexOncology will:

Prepare a statistical analysis plan (SAP) that is in accordance with the objectives of the final study protocol. The SAP is typically comprised of a protocol summary including study endpoint definitions, mock-up templates for the analysis tables, listings and figures to be included in the clinical study report, and a description of technical programming and/or analysis instructions. Shuttle will review and approve the SAP. Theradex Oncology assumes two reviews of the document.

| Page 20 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | B. | Generate tables and data listings and figures for data analysis using SAS® software. Descriptive statistics will be provided for demographic, adverse event, laboratory, and response data. Patient narratives, if required, will be provided. Theradex Oncology will create a draft package of mock-up templates for the analysis tables and listings to be included in the final clinical study report, as part of the SAP. The mock-up templates will contain the information collected on the CRF in the form of summary tables and patient listings. | | --- | --- | | TLFs Programming | | | --- | --- | | # of Tables – Unique | 37 | | # of Tables – repeat | 21 | | # of Listings – Unique | 31 | | # of Listings – Repeat | 4 | | # of Figures – Unique | 3 | | # of Figures - Repeat | 2 | | C. | Prepare analysis-datasets and execute the programs to generate the final tables and listings after completion of the database lock. SDTM programming is not foreseen as part of the scope of this project. | | --- | --- | | D. | Perform a Quality Control (QC) check of tables and listings and figures in accordance with Theradex Oncology’s SOP. | | --- | --- | | 1.7 | Data Management Services | | --- | --- | | 1.7.1 | Patient Registration System, Monitor Express and Client Portal | | --- | --- | | Task List | Shuttle | Theradex | | --- | --- | --- | | Design Registration Script | | X | | Configure Registration System | | X | | Manage Registration System | | X | | Configure and Manage Monitor Express | | X | | Train Users | | X |

TheradexOncology will:

A.	Set<br> up and maintain Theradex Oncology’s proprietary automated interactive web registration<br> system (IWRS) for patient enrollment.
B.	Test,<br> validate, and QC the system prior to implementation.
---	---

| Page 21 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | C. | Provide user training and user name and password information for each user for the IWRS. Access to the IWRS will be through a secure https connection. Access to the IWRS at the site level will be determined at the start of the study. All IWRS screens will be displayed in English. | | --- | --- | | D. | Provide a user manual for the IWRS with step-by-step instructions for enrolling a patient as well as user management. The IWRS will collect the site ID and username. Actual enrollment will proceed by collecting a local patient ID (for audit tracking), the patient’s gender and any other necessary information that may be required for either registration or randomization. When appropriate, Shuttle and Theradex Oncology will agree upon the stratification factors in the protocol. Following each entry into the IWRS a fax and/or email confirmation will be sent to the user, the site, Shuttle and Theradex Oncology clinical staff. | | --- | --- | | E. | Provide support and technical assistance 8:00 am to 8:00 pm U.S. Eastern Time to answer routine questions. Theradex Oncology will provide a caller ID to the central site, which will allow enrollment at any sub-site. | | --- | --- | | F. | Configure, prepare, and manage Monitor Express for CRA centralized access to all study related databases and as a tool for Shuttle to have real time access to monitor findings. | | --- | --- | | 1.8 | Data Management (EDC) | | --- | --- | | Task List | Shuttle | Theradex | | --- | --- | --- | | Data Management Plan | | X | | Approve Data Management Plan | X | | | Design and draft eCRFs | | X | | Approve eCRFs | X | | | EDC Event Set-Up | | X | | Write EDC User Manual | | X | | EDC Training | | X | | Database development | | X | | Reconciliation of Safety and Clinical databases | | X | | Edit Check | | X | | Adverse Event and Medication coding | | X | | Database QC and database lock | | X | | SAS dataset | | X | | Prepare Data Transfer Plan | | X | | Transfer Data | | X |

TheradexOncology will:

A.	Design<br> and program the electronic case report forms (eCRFs) based upon the protocol provided by<br> Shuttle. Theradex Oncology assumes this study will require no more than 55 unique forms,<br> of which 80% are from the Theradex Oncology global library, requiring minimal customization.<br> Shuttle will review and approve the eCRFs prior to implementation. Only one round of changes<br> is assumed. Customization of forms and/or changes that exceed these limits can result in<br> additional costs.
B.	Use<br> Electronic Data Capture (EDC) for this project. The sites will enter the data directly into<br> the EDC system. The EDC data is maintained in an Zelta Clinical Development database. Data<br> entry instructions for the sites will be incorporated within the EDC system, in order to<br> provide guidance on entry procedures specific to the study.
---	---
C.	Provide<br> an Initial EDC training session for the clinical centers.
---	---
D.	Prepare<br> a Data Management Plan outlining data collection and flow processes ongoing throughout the<br> study. Theradex Oncology’s standard format will be used, provided that Shuttle will<br> review and approve the Data Management Plan prior to finalization.
---	---

| Page 22 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | E. | Set up a study database. Theradex Oncology’s standard study database format will be utilized. Included in the database are data entry/data posting programs, audit listing programs, CRF tracking and delinquency programs. Each program is validated and 21 CFR Part 11 compliant. | | --- | --- | | F. | Design and program global electronic case report forms (eCRFs) based upon the protocol provided by Shuttle. Shuttle will approve the eCRFs prior to implementation. Theradex Oncology assumes two sponsor reviews of each eCRF. | | --- | --- | | G. | Utilize generic edit checks which are programmed into the database. Protocol-specific parameters may be supplied at study start-up and additional checks may be programmed as needed. Data exceptions identified by the edit checks may be reviewed and queried as deemed appropriate by clinical staff. Theradex Oncology assumes no more than 150-200 custom edit checks will be programmed. If more custom Edit Checks are necessary, additional costs may apply. | | --- | --- | | H. | Review all data for completeness and clarity, ensuring that there are no inconsistent or unexpected data. Theradex Oncology will evaluate all data for both safety and efficacy and will resolve any data conflicts or internal inconsistencies. EDC data will be reviewed prior to each monitoring visit. | | --- | --- | | I. | Process data utilizing Theradex Oncology’s standard study database format where possible. The Theradex Oncology team will work with Shuttle to reduce the total number of data tables and data points captured to reduce the overall cost of data management services to Shuttle and to increase the likelihood of compliance with timeliness of data reporting. | | --- | --- | | J. | Prepare data entry instructions in order to provide guidance on entry procedures specific to the study. | | --- | --- | | K. | Prepare, issue and resolve (e.g., issue data queries for) missing and/or incomplete data. Theradex Oncology will prepare and track each data query and follow-up with the study sites to ensure that all data queries are resolved in a timely manner. | | --- | --- | | L. | Code adverse events, concomitant medications and site of disease/histology using the MedDRA, WHO-DD and ICD-O dictionaries. | | --- | --- |

| Page 23 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 | | M. | Perform a final database audit after the data have been entered, cleaned and coded, and queries resolved (details to be provided in the data management plan). Theradex Oncology will supply a record of the audit to Shuttle within ten days of completion. Once the final database is locked, Theradex Oncology will transmit the final datasets to Shuttle. | | --- | --- | | N. | Perform a Final Database Lock and Data Transfer. | | --- | --- | | O. | Prepare Data Transfer Plans according to Theradex Oncology SOPs and manage data transfers. Theradex Oncology will reconcile all external data with the clinical database. | | --- | --- | | P. | Perform SAS® data transfer to Shuttle 5 times throughout the duration of the study. This includes one test transfer and the associated validation. | | --- | --- | | Q. | Transfer all data to Shuttle. | | --- | --- |

The deadlines for sponsor approval of IWRS and EDC specifications are critical to keeping the project on schedule. Delays in approval can result in significant launch delays.

1.9	Investigational Drug Management
Task List	Shuttle	Theradex	Theradex separate work order
---	---	---	---
Sponsor<br> Coordination			X
Investigational<br> Product Receipt			X
Investigational<br> Product Shipments			X
Investigational<br> Product Labeling			X
Investigational<br> Product Storage Maintenance			X
Inventory<br> Reporting/tracking			X
Investigational<br> Product Destruction			X

TheradexOncology will:

A.	Not<br> applicable for this work order. IMP services are conducted by Theradex Oncology under a separate<br> work order (WO#2).

| Page 24 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

Appendix2: Theradex Oncology Project Budget

Theradex Oncology Project Budget Summary

[***]

| Page 25 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

Milestone Payment Schedule

[***]

| Page 26 of 30 |

| --- |

| Shuttle Pharmaceuticals, Inc. |  |

| --- | --- | | Work Order #3: Phase 2 IPdR Glioblastoma study | 30 July 2024 |

Pass Through Cost Summary

[***]

License Fee Summary

[***]

| Page 27 of 30 |

| --- |

Exhibit 10.2

Exhibit 99.1

ShuttlePharma Ready to Enroll patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

GAITHERSBURG, Md., August 14, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Site initiation visits have been completed for two sites. The trial is now open to enroll patients in the clinical trial.

Ropidoxuridine (IPdR) is Shuttle Pharma’s lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation from the FDA, providing potential marketing exclusivity upon first FDA approval for the disease.

The Phase 2 clinical trial will be conducted on patients with the most aggressive brain tumors out there – IDH wild-type, methylation negative glioblastoma. Presently, radiation is the only approved standard of care for this particular group of patients , with more than half of the patients surviving for less than 12 months after diagnosis. Shuttle Pharma’s Phase 2 clinical trial will consist initially of 40 patients randomized into two different doses (20 @ 1,200 mg/day and 20 @ 960 mg/day) to determine an optimal dose. Once the Company determines the optimal dose, it will then add an additional 14 patients on the optimal dosage allowing for the achievement of statistical significance with the end point being that of survival as compared to historical controls. The Company expects the trial to be completed over a period of 18 to 24 months.

“We are pleased to be working with highly talented teams at academic medical centers on our Phase 2 trial of Ropidoxuridine for the treatment of patients with glioblastoma,” commented Shuttle Pharma’s Chairman and CEO, Anatoly Dritschilo, M.D. “The results of this trial will be important to the cancer community as we look for ways to leverage radiation sensitizers to increase cancer cure rates, prolong patient survival and improve quality of life for patients suffering from glioblastoma.”

Shuttle Pharma expects the Phase 2 clinical trial will be carried out at six site locations, with all sites anticipated to be treating patients in the coming months.

“We have carefully selected six universities and hospitals that are most likely to treat IDH wild-type, methylation negative glioblastoma patients which should allow for more rapid enrollment of the Phase 2 trial,” added Dr. Tyvin Rich, Chief Medical Officer of Shuttle Pharma and Professor Emeritus of Radiation Oncology, University of Virginia School of Medicine.

An estimated 800,000 patients in the US are treated with radiation therapy for their cancers yearly. According to the American Cancer Society and the American Society of Radiation Oncologists, about 50% are treated for curative purposes and the balance for therapeutic care. The market opportunity for radiation sensitizers lies with the 400,000 patients treated for curative purposes, with this number expected to grow by more than 22% over the next five years.

More information about the Phase 2 study (NCT06359379) can be found at www.clinicaltrials.gov.

AboutShuttle Pharmaceuticals

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.

SafeHarbor Statement

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 20, 2024, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

ShuttlePharmaceuticals

Anatoly Dritschilo, M.D., CEO

240-403-4212

info@shuttlepharma.com

InvestorContacts

Lytham Partners, LLC

Robert Blum

602-889-9700

shph@lythampartners.com